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The phosphoenolpyruvate 
carboxykinase (PEPCK) inhibitor, 
3‑mercaptopicolinic acid (3‑MPA), 
induces myogenic differentiation 
in C2C12 cells
Madelaine C. Brearley1,3, Zoe C. T. R. Daniel1, Paul T. Loughna2, Tim Parr1 & 
John M. Brameld1*
Phosphoenolpyruvate carboxykinase (PEPCK) is a gluconeogenic enzyme with a cytosolic 
(Pck1/PEPCK‑C) and mitochondrial (Pck2/PEPCK‑M) isoform. Here we investigate the effect of 
3‑mercaptopicolinic acid (3‑MPA), a PEPCK inhibitor, on C2C12 muscle cells. We report that Pck2 
mRNA is 50–5000‑fold higher than Pck1 during C2C12 myogenesis, indicating Pck2 is the predominant 
PEPCK isoform. C2C12 cell proliferation was inhibited in a dose‑dependent manner following 48 h 
3‑MPA treatment (0.01–1 mM). C2C12 myogenic differentiation was significantly induced following 
3‑MPA treatment (0.25, 0.5, 1 mM) from day 0 of differentiation, demonstrated by increased creatine 
kinase activity, fusion index and myotube diameter; likewise, the myosin heavy chain (MyHC)‑IIB 
isoform (encoded by Myh4) is an indicator of hypertrophy, and both porcine MYH4‑promoter activity 
and endogenous Myh4 mRNA were also significantly induced. High doses (0.5 and/or 1 mM) of 3‑MPA 
reduced mRNA expression of Pck2 and genes associated with serine biosynthesis (Phosphoglycerate 
dehydrogenase, Phgdh; phosphoserine aminotransferase‑1, Psat1) following treatment from days 
0 and 4. To conclude, as Pck2/PEPCK‑M is the predominant isoform in C2C12 cells, we postulate that 
3‑MPA promoted myogenic differentiation through the inhibition of PEPCK‑M. However, we were 
unable to confirm that 3‑MPA inhibited PEPCK‑M enzyme activity as 3‑MPA interfered with the PEPCK 
enzyme assay, particularly at 0.5 and 1 mM.
We previously reported that β2-adrenergic receptor agonist (BA)-induced muscle hypertrophy in pigs was associ-
ated with a coordinated upregulation of a novel group of genes associated with an integrated stress  response1,2, 
including mitochondrial phosphoenolpyruvate carboxykinase (Pck2) and genes involved in serine biosynthe-
sis (phosphoglycerate dehydrogenase, Phgdh; phosphoserine aminotransferase-1, Psat1). We also reported a 
coordinated upregulation in mRNA expression of this same group of genes at day 2 of differentiation in C2C12 
muscle cells, which coincided with the peak in myogenin  expression3, suggesting that they might be important 
for myogenic differentiation.
Phosphoenolpyruvate carboxykinase (PEPCK) is a gluconeogenic enzyme that converts oxaloacetate to 
phosphoenolpyruvate (PEP), but is also involved in amino acid synthesis, glyceroneogenesis and  cataplerosis4. 
There are two isoforms: the cytosolic isoform (PEPCK-C) encoded by Pck1 and the mitochondrial isoform 
(PEPCK-M) encoded by Pck2. Previous studies looking into PEPCK function focussed on the role of PEPCK-
C in hepatic gluconeogenesis and its involvement in type-2 diabetes, due to its tight hormonal  regulation4. 
Although PEPCK-M was found to be constitutively expressed, it was classed as the ‘inferior’ isoform and its 
specific role was overlooked for many years, until recently when it was identified as an important regulator of 
cancer cell  metabolism5,6. 3-Mercaptopicolinic Acid or 3-Mercaptopicolinate (3-MPA), a known inhibitor of 
gluconeogenesis, has been reported to inhibit both isoforms of PEPCK, but with increased potency for PEPCK-C 
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in vitro7–9. The aim of this study was to compare the endogenous expression of Pck1 and Pck2 in proliferating 
and differentiating C2C12 cells and then determine the dose-dependent effects of the PEPCK inhibitor, 3-MPA, 
on proliferation, differentiation and gene expression of C2C12 cells.
Results
Treatment with 3‑MPA inhibits proliferation of C2C12 cells. C2C12 cells were treated with a range 
of 3-MPA doses (0–1 mM) and total DNA content quantified as a marker of total cell number. There was a sig-
nificant time × treatment interaction (P < 0.001), with 3-MPA inducing a dose-dependent (0.1–1 mM) reduction 
in total DNA content compared to the vehicle control (PBS; 0 mM 3-MPA) but only after 24 and 48 h treat-
ment (Fig. 1a). In the presence of 1 mM 3-MPA, total DNA content increased with time and was higher than 
cells treated with 2% (v/v) FBS, particularly after 48 h. This suggests that there were no or limited toxic effects 
within the range of 3-MPA doses used, although cell viability or toxicity were not determined. The reduction in 
cell number after 48 h of treatment (Fig. 1b) is consistent with the significant reduction in BrdU incorporation 
(Fig. 1c), particularly with the higher doses of 3-MPA (0.1–1.0 mM). This suggests that treatment with 3-MPA 
reduces total cell number in a dose-dependent manner, probably as a result of inhibiting cell proliferation.
Treatment with 3‑MPA induces myogenic differentiation of C2C12 cells. Treatment of C2C12 
cells with increasing doses of 3-MPA (0.25, 0.5 and 1 mM) from day 0 of differentiation resulted in larger myo-
tubes being observed at day 5 (Fig. 2a). With increasing doses of 3-MPA, cells became sparser but resulted in 
more round bulging cells and much larger myotubes. These observations are comparable to those reported pre-
viously by our group in C2C12 cells treated with dbcAMP from day 0 of  differentiation3. Creatine kinase (CK) 
activity is an established indicator of myogenic differentiation, therefore we next quantified CK activity every 
24 h following treatment with 3-MPA from day 0 until day 5. There was a significant time × treatment interaction 
for CK activity normalised for DNA (P = 0.014; Fig. 2b), due to cells treated with 0.5 or 1 mM 3-MPA having 
increased CK activity at days 4 and 5, indicating that these higher doses of 3-MPA induced greater myogenic 
differentiation compared to the control.
Myosin Heavy Chain (MyHC)-IIB isoform expression is often associated with hypertrophic growth. We 
recently reported the response of the porcine MYH4 promoter to various known anabolic and catabolic agents 
Figure 1.  Treatment with 3-MPA reduced C2C12 cell number by inhibiting proliferation. Proliferating 
C2C12 cells were treated with a range of 3-MPA doses (0.01–1 mM) or equivalent volume of vehicle control 
(PBS; 0 mM 3-MPA) diluted in GM supplemented with 5% (v/v) FBS. (a) Cells were collected for total DNA 
quantification after 0, 8, 24 and 48 h of treatment. Data presented as Means (n = 16) ± SEM. Two-way ANOVA 
was performed: #P < 0.001 (time × treatment interaction). Cells were also either (b) collected to quantify total 
DNA content after 48 h or (c) incubated with BrdU labelling solution for the final 3 h of the 48 h period 
to quantify BrdU incorporation. The data presented in (a) and (b) were obtained in separate experiments. 
Data presented as Means (n = 8) ± SEM. One-way ANOVA was performed, followed by a Dunnett’s multiple 
comparison to vehicle control (0 mM 3-MPA): *P < 0.05, **P < 0.01 and ***P < 0.001. 2% and 10% (v/v) FBS were 
internal controls and therefore excluded from the statistical analyses.
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:22177  | https://doi.org/10.1038/s41598-020-79324-9
www.nature.com/scientificreports/
using a fluorescence-based promoter-reporter  system10, here we utilise the same system to determine the effects 
of 3-MPA treatment on both porcine MYH4-promoter activity and myotube diameters simultaneously. dbcAMP 
treatment was used as a positive control and, as expected, dbcAMP treatment significantly increased both MYH4-
promoter activity (P = 0.007) and myotube diameters (P = 0.009). Similarly, 3-MPA treatment (at 0.25 and 1 mM) 
also induced both porcine MYH4-promoter activity (P = 0.03; Fig. 2c) and myotube diameter (P < 0.001; Fig. 2d).
Treatment with 3‑MPA increases fusion index in C2C12 cells. Fusion index is the percentage of 
nuclei per field of view found inside MyHC positive (MyHC+) cells and is another indicator of myogenic dif-
Figure 2.  Treatment with 3-MPA induces myogenic differentiation. C2C12 cells were treated with 0, 0.25, 0.5 or 
1 mM 3-MPA from day 0 of differentiation for five days, with DM refreshed every 48 h. Samples were collected 
every 24 h for six days and a Creatine Kinase (CK) activity assay performed. (a) Representative bright-field 
images captured at day 5 of treatment with 0, 0.25, 0.5 or 1 mM 3-MPA. Photographs were captured at ×6.3 
magnification. Scale bar: 100 µm. Data presented as Means (n = 3, except day 0 n = 6) ± SEM for (b) CK activity 
normalised to DNA content. #P < 0.05 (time × treatment interaction). C2C12 cells were transfected with MYH4-
ZsGreen expression plasmid on day − 1, then treated with 0, 0.25 or 1 mM 3-MPA from day 0 until day 4 of 
differentiation. Measurements were taken for (c) porcine MYH4-promoter activity and (d) average myotube 
diameter. Data presented as Means ± SEM, from three wells for MYH4-promoter activity (n = 3) and five separate 
fields of view per well for myotube diameter (n = 15). (c) Student’s t-test was used for dbcAMP treatment and 
one-way ANOVA for 3-MPA doses and (d) one-way ANOVA (blocking for ‘well’) were performed for each 
treatment group and appropriate vehicle controls, followed by a post-hoc Dunnett’s multiple comparison test for 
3-MPA doses compared to the vehicle control (PBS; 0 mM 3-MPA). *P < 0.05, ***P < 0.001.
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ferentiation (Fig. 3a). Average fusion index was significantly increased following 0.25 mM 3-MPA treatment 
compared to control (P < 0.001; Fig.  3b). There was a significant treatment × number of nuclei interaction 
(P < 0.001; Fig. 3c), whereby the frequency of MyHC+ cells containing one, two or three nuclei demonstrated 
a dose-dependent reduction with increasing doses of 3-MPA compared to the control; however, the frequency 
of MyHC+ cells containing 10+ nuclei was increased with 3-MPA treatment, particularly at 0.25 mM. MyHC+ 
cells treated with 3-MPA were observed to contain 40 or more nuclei, whereas control cells showed a maximum 
of ~ 20 nuclei. Similarly, the total number of nuclei within MyHC+ cells was significantly affected by 3-MPA 
treatment (P = 0.02; Fig. 3d) where 0.25 mM, but not 0.5 or 1 mM, resulted in a significant increase in the total 
number of nuclei within MyHC+ cells.
Figure 3.  Treatment with 3-MPA increases fusion index. C2C12 cells were treated with 0, 0.25, 0.5 or 1 mM 
3-MPA from day 0 of differentiation, then after 72 h treatment immunofluorescence was performed using 
MyHC antibody (green) and PI (red). (a) Photographs captured at 10X magnification. Scale bar: 100 µm. ImageJ 
software was used to quantify (b) Fusion Index, (c) the frequency of nuclei found within MyHC+ cells and 
(d) total nuclei number within MyHC  cells. Data presented as Means (n = 12, from four wells per treatment 
and three fields of view per well) ± SEM. One- or two-way ANOVAs (blocking for ‘well’) were performed as 
appropriate, followed by Dunnett’s comparison test to the vehicle control (PBS; 0 mM 3-MPA). #P < 0.001 
(treatment × nuclei number interaction) *P < 0.05, ***P < 0.001.
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Treatment with 3‑MPA alters mRNA expression of genes associated with myogenesis. There 
was a significant time × treatment interaction (P = 0.02) for myogenin (encoded by Myog) mRNA expression 
following treatment with 3-MPA (0.25–1 mM) from day 0 of differentiation, but not from day 4 (P = 0.177). As 
observed  previously3, myogenin mRNA peaked at day 2 of differentiation then decreased with differentiation 
(Fig. 4a). Treatment with 1 mM 3-MPA from day 0 resulted in lower myogenin mRNA compared to the control 
at days 2 and 4; however, there was no effect of treatment (P = 0.118; Fig. 4b) or time (P = 0.859) following 3-MPA 
treatment from day 4. See Supplementary Table 1 for a summary of Dunnett’s Multiple Comparison tests.
There were significant time × treatment interactions for Myh7 (encodes slow oxidative MyHC-I isoform) 
mRNA following 3-MPA treatment from both day 0 (P = 0.008, Fig. 4c) and day 4 (P < 0.001, Fig. 4d). As observed 
 previously3, Myh7 mRNA was expressed from day 1, whereas 3-MPA treatment from day 0 generally reduced 
Figure 4.  Effect of 3-MPA treatment on genes associated with myogenesis. Relative expression of (a, b) Myog 
(Myogenin), (c, d) Myh7 (encodes Myosin Heavy Chain (MyHC)-I), and (e, f) Myh4 (encodes MyHC-IIB) 
mRNA following treatment of C2C12 cells with 0, 0.25, 0.5 or 1 mM 3-MPA from day 0 (a, c, e) or day 4 (b, d, 
f) of differentiation. Data presented as Means (n = 4–6) ± SEM. #P < 0.05 (time × treatment interaction). Start of 
treatment indicated by ↑. See Supplementary Tables 1 and 2 for Dunnett’s Multiple Comparison tests.
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Myh7 mRNA after 48 h treatment (day 2) at all doses, particularly 1 mM, but had inconsistent effects at other 
time points (Fig. 4c). In contrast, treatment with 3-MPA from day 4 of differentiation resulted in a clear dose-
dependent reduction in Myh7 mRNA between days 6 and 8 (Fig. 4d). See Supplementary Tables 1 and 2 respec-
tively for summaries of Dunnett’s Multiple Comparison tests following treatment from day 0 and day 4. There 
was also a significant time × treatment interaction for Myh4 (encodes fast glycolytic MyHC-IIB isoform) mRNA 
following 3-MPA treatment from day 0 (P < 0.001, Fig. 4e), however only a trend was observed following treat-
ment from day 4 (P = 0.097, Fig. 4f). Treatment with 3-MPA from day 0 resulted in a dose-dependent increase in 
Myh4 mRNA from day 3 onwards (Fig. 4e); whereas there was a significant increase in Myh4 mRNA expression 
with time (P < 0.001; Fig. 4f), but no effect of 3-MPA treatment from day 4 (P = 0.548).
Endogenous mRNA expression of PEPCK isoforms during differentiation of C2C12 cells. The 
level of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C encoded by Pck1) isoform mRNA was very 
lowly expressed in C2C12 cells and consequently an accurate standard curve could not be generated for this 
gene. As a result we compared crossing point (Cp) values for the two PEPCK isoforms to approximate changes in 
transcript levels during myogenic differentiation. In proliferating myoblasts (days − 1 and 0), the mitochondrial 
PEPCK isoform (PEPCK-M encoded by Pck2) was over 2500-fold (11.5 Cp values; Table 1) higher than Pck1 
and on average over 200-fold (8 Cp values, Table 1) higher in differentiated myotubes (days 4–8); therefore, this 
indicates that Pck2 is the predominant PEPCK isoform in C2C12 cells.
Treatment with 3‑MPA alters mRNA expression of genes associated with gluconeogenesis 
and serine biosynthesis. There was no time × treatment interaction for Pck2 mRNA expression following 
treatment from day 0 (P = 0.119), however there were significant effects of time and 3-MPA treatment separately 
(both P < 0.001; Fig. 5a). Relative mRNA expression of Pck2 was higher in proliferating myoblasts than differen-
tiated myotubes and a peak at day 2 of differentiation was observed that coincided with the peak in myogenin 
mRNA, as reported  previously3. There was a significant time × treatment interaction on Pck2 mRNA expression 
following 3-MPA treatment from day 4 (P = 0.006; Fig. 5b), with 0.5 and 1 mM 3-MPA reducing Pck2 mRNA at 
days 5 and 7, whereas treatment with 0.25 mM 3-MPA only reduced Pck2 mRNA at day 7.
There was a significant time × treatment interaction for phosphoglycerate dehydrogenase (Phgdh) mRNA 
expression following 3-MPA treatment from day 0 and day 4 (both P < 0.001; Fig. 5c,d). Relative Phgdh mRNA 
was higher in proliferating myoblasts at day − 1 than differentiated myotubes and indicated a similar day 2 peak 
that coincided with myogenin and Pck2 mRNA, as observed  previously3. Treatment with 3-MPA (0.25, 0.5 and 
1 mM) from day 0 of differentiation generally reduced Phgdh mRNA between days 3 and 5 (Fig. 5c), whereas 
3-MPA treatment from day 4 reduced Phgdh mRNA at all time-points (between days 5 and 8; Fig. 5d).
There was no time × treatment interaction for phosphoserine aminotransferase-1 (Psat1) mRNA expression 
following 3-MPA treatment from day 0 (P = 0.109), but there were significant effects of time (P < 0.001) and 
3-MPA (P = 0.018) separately. Relative mRNA expression of Psat1 was higher in proliferating myoblasts at day 
− 1 than differentiated myotubes (Fig. 5e,f) and treatment with 3-MPA (0.25, 0.5 and 1 mM) generally reduced 
Psat1 at days 3 and 5 (Fig. 5e). There was a significant time × treatment interaction for Psat1 mRNA following 
3-MPA treatment from day 4 (P < 0.001), with 3-MPA treatment (0.25, 0.5 and 1 mM) reducing Psat1 mRNA 
between days 5 and 7 (Fig. 5f).
Discussion
For the first time we report the effects of the gluconeogenic inhibitor, 3-mercaptopicolinic acid (3-MPA), on 
proliferation and myogenic differentiation of C2C12 cells. 3-MPA treatment (0.01–1 mM) inhibited cell prolifera-
tion (total DNA and BrdU incorporation) in a dose-dependent manner and induced myogenic differentiation 
(CK assay) at 0.5 and 1 mM. Interestingly, 3-MPA resulted in similar effects to those observed previously with 
dbcAMP treatment of C2C12 cells from day  03; including significant increases in myotube diameters, porcine 
MYH4-promoter activity and endogenous Myh4 mRNA expression. These results were contrary to our original 
hypothesis that mitochondrial phosphoenolpyruvate carboxykinase (Pck2/PEPCK-M) was important for myo-
genesis and therefore inhibition would result in myotube atrophy. However they do agree with our recent finding 
that Pck2 overexpression in mouse skeletal muscle, via intramuscular injection of an AAV construct, results in 
a decrease in muscle  weights11.
We also make the novel observation that mitochondrial Pck2 is the predominant PEPCK isoform in C2C12 
cells, with cytosolic Pck1 mRNA being significantly lower (50–5000-fold) than Pck2 mRNA throughout C2C12 
myogenic differentiation. Therefore, we suggest that the phenotypic responses observed in this study were prob-
ably a result of PEPCK-M inhibition, although this still requires confirmation. The effect of 3-MPA on mRNA 
transcript abundance was different following treatment of C2C12 cells at the onset of differentiation (from day 
0) compared to treatment of differentiated myotubes (from day 4), with effects mainly observed with the higher 
Table 1.  Average Crossing Point (Cp) values for murine Pck1 and Pck2 mRNA expression in C2C12 cells 
during myogenic differentiation.
Day − 1 0 1 2 3 4 5 6 7 8
Pck1 37.5 37.2 36.2 35.8 35.9 35.4 35.6 36.7 36.8 34.0
Pck2 25.9 25.7 27.1 26.6 27.0 27.6 27.4 27.8 27.4 28.1
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doses of 3-MPA (0.5 and 1 mM). We previously reported coordinated increases in Pck2 mRNA and the genes 
involved in serine biosynthesis (Phosphoglycerate dehydrogenase, Phgdh; Phosphoserine aminotransferase-1, 
Psat1) following BA-induced hypertrophy in porcine skeletal  muscle1, as well as during C2C12 cell myogenic 
 differentiation3. The data presented here supports the synchronous nature and possible coordinated regulation 
of Pck2 mRNA and the serine biosynthesis genes (Phgdh and Psat1), since treatment with 3-MPA from day 0 or 
day 4 resulted in significant reductions in Pck2, Phgdh and Psat1 mRNA expression, albeit at slightly different 
timepoints (Fig. 5).
Treatment with 3-MPA from day 0 or day 4 of differentiation either reduced or had no effect on myogenin 
mRNA respectively. However, 3-MPA significantly increased Myh4 mRNA, the Myosin Heavy Chain (MyHC)-IIB 
Figure 5.  Effect of 3-MPA treatment on genes associated with gluconeogenesis and serine biosynthesis. Relative 
expression for (a, b) Pck2 (encodes mitochondrial PEPCK isoform), (c, d) phosphoglycerate dehydrogenase 
(Phgdh) and (e, f) phosphoserine aminotransferase-1 (Psat1) mRNA following treatment of C2C12 cells with 
0, 0.25, 0.5 or 1 mM 3-MPA from day 0 (a, c, e) or day 4 (b, d, f) of differentiation. Data presented as Means 
(n = 4–6) ± SEM. #P < 0.05 (time × treatment interaction). Start of treatment indicated by ↑. See Supplementary 
Tables 1 and 2 for Dunnett’s Multiple Comparison tests.
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isoform often associated with hypertrophy, particularly with treatment from day 0. This is similar to the previ-
ously observed effects of  dbcAMP3, however there were no effects when C2C12 myotubes were treated with 
3-MPA from day 4. In contrast, 3-MPA treatment from day 0 had little effect on Myh7 (encodes slow oxidative 
MyHC-I isoform) mRNA, whereas treatment with increasing doses of 3-MPA from day 4 induced a dose-
dependent reduction in Myh7 mRNA.
Computational analysis of the structure for rat cytosolic PEPCK (i.e. Pck1) indicate that 3-MPA binds to 
both the PEP/OAA active site and an allosteric site that helps stabilise the  enzyme12. It is unclear whether the 
same mechanism applies to mitochondrial PEPCK (PEPCK-M/ Pck2), but 3-MPA treatment of lung cancer cell 
lines induced similar responses to that of PEPCK-M gene specific knock-down6. Since we show that PEPCK-M 
is the predominant PEPCK isoform in C2C12 cells, we assume that the responses observed are mainly due to 
inhibition of PEPCK-M. It has previously been reported that 3-MPA inhibits PEPCK  activity13, but the high-
est dose studied was 0.1 mM. We found that 3-MPA appeared to interfere with the PEPCK enzymatic activity 
assay used previously by our  group11, particularly at the higher doses > 0.25 mM (see Supplementary Tables 3, 
4 and 5). Therefore, it is unclear whether or not the effects of 3-MPA on C2C12 cell proliferation, differentia-
tion, hypertrophy and gene expression are due to inhibition of PEPCK-M activity. Although 3-MPA has been 
reported as a highly selective PEPCK inhibitor at 0.3 mM in Trypanosoma cruzi, with minimal or no effects on 
other  enzymes14, it has also been shown that millimolar concentrations of 3-MPA inhibit Glucose-6-phosphate 
translocase in isolated rat  livers15. Therefore, it is possible that the responses to the higher doses (0.5 and 1 mM) 
of 3-MPA observed in C2C12 cells may be due to effects on other enzymes.
Conclusions
Contrary to initial expectations, treatment of C2C12 cells with 3-MPA induced myogenic differentiation, includ-
ing increases in CK activity, fusion index and myotube diameters, as well as increasing porcine MYH4-promoter 
activity and endogenous Myh4 mRNA expression. This induction of differentiation was associated with a con-
comitant decrease in cell proliferation, which is as expected, given that C2C12 cells need to exit the cell cycle and 
therefore stop proliferating before they can terminally differentiate into myotubes. These responses are similar 
to the effects of dbcAMP on C2C12 cells we previously  reported3 and do agree with our recent observation that 
Pck2 overexpression in mouse muscle results in reduced muscle  weights11. However, as 3-MPA interfered with 
the PEPCK activity assay, it is unclear whether these novel observations, particularly at higher doses (0.5 and 
1 mM), are due to PEPCK-M inhibition or a result of off-target effects, but the pro-myogenic effect of 3-MPA 
was accompanied by inhibition of genes involved in gluconeogenesis and serine synthesis. It would be useful to 
determine if 3-MPA inhibits PEPCK-M activity at these higher doses, as well as any effects on other enzymes.
Methods
3‑MPA treatment. 3-MPA (SC-206655, Santa Cruz Biotechnology) was dissolved in phosphate buffered 
saline (PBS), filtered through a 20 µm filter and stock solution aliquots (20 mM) stored at − 20 °C. 3-MPA was 
diluted firstly in PBS followed by a 1:10 dilution into culture media, providing a concentration range of 0.01 
to 1 mM, based on previously reported in vitro  studies8,9,16. C2C12 cell stocks were originally purchased from 
the European Collection of Authenticated Cell Cultures (ECACC; 91031101) and checked regularly for myco-
plasma. They were initially cultured in Growth Medium (GM; high (25 mM) glucose Dulbecco’s modified eagle’s 
medium (DMEM; Sigma-Aldrich, Poole, UK) supplemented with 10% (v/v) foetal bovine serum (FBS) and 1% 
(v/v) penicillin/streptomycin (P/S)). Once the cells reached ~ 80% confluence (day 0), they were switched to Dif-
ferentiation Medium (DM; high glucose (25 mM) DMEM supplemented with 2% (v/v) horse serum (HS) and 
1% (v/v) P/S). Media was refreshed every 48 h. All treatments were made up fresh on the day of treatment and 
equivalent volume of PBS (0 mM 3-MPA) was used as the vehicle control, such that the dilution of the media 
was constant for all treatments.
Total DNA content and BrdU incorporation assay. C2C12 cells were seeded at 2500 cells per well 
onto black-walled, clear-bottomed 96-well plates and left to settle overnight. Cells were treated at ~ 20% conflu-
ence with a range of 3-MPA doses (0–1 mM) added to GM supplemented with 5% (v/v) FBS for up to 48 h, then 
assays were performed directly onto 96-well plates. DNA assays were performed as described  previously17,18 
and BrdU incorporation assay was carried out according to the manufacturers guide for the Cell Proliferation 
(chemiluminescent) ELISA kit (Roche Diagnostics, Mannheim, Germany). Cells were treated with GM sup-
plemented with either 2% or 10% (v/v) FBS to act as internal controls and determine the effective range for the 
two assays.
Creatine kinase activity assay. C2C12 cells were seeded at 150,000 cells per well onto 6-well plates. At 
~ 80% confluence (day 0 of differentiation), cells were switched to DM supplemented with a range of 3-MPA 
doses (0–1 mM). DM was then refreshed every 48 h and wells harvested every 24 h from day 0 for six days to 
determine creatine kinase (CK) activity. CK activity assay was performed as described  previously17,18.
Fusion index assay. C2C12 cells were seeded at 60,000 cells per well of a 12-well plate and subsequently 
switched to DM supplemented with a range of 3-MPA doses (0–1 mM) at ~ 80% confluence (day 0 of differen-
tiation). After 72 h treatment, C2C12 cells were fixed using ice cold 100% (v/v) methanol, washed in PBS, then 
blocked for 1 h in 1% (v/v) Triton-X (Sigma-Aldrich) and 10% HS. Cells were incubated at 4 °C overnight with 
Myosin antibody (Developmental Studies Hybridoma Bank, Iowa, USA) diluted 1:1000 in 0.5% (v/v) Triton-X 
and 10% (v/v) HS. Cells were washed in PBS, then incubated at room temperature for 2 h with 1:1000 diluted 
Alexa Fluor-488 conjugated secondary antibody (Thermo Fisher, Illinois, USA) to detect all Myosin Heavy 
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Chain (MyHC) isoforms (green), referred to as MyHC+ cells. Propidium Iodide solution (PI; Sigma-Aldrich, 
Missouri, USA) was diluted 1:3000 and incubated with cells for 15 min to stain cell nuclei red. Photographs were 
captured using a Leica fluorescent microscope for three randomly selected fields of view per well and four wells 
per treatment (n = 12). Frequency of nuclei and total number of nuclei found within MyHC+ cells per field of 
view were determined using ImageJ software. Fusion Index (%) was quantified as follows:
Porcine MYH4‑promoter activity and myotube diameter. C2C12 cells were seeded at 25,000 cells 
per well of a 24-well plate and co-transfected with porcine MYH4-ZsGreen and CMV-DsRed expression plas-
mids between 50 and 60% confluence as previously  described10. At ~ 80% confluence, cells were switched to DM 
(day 0 of differentiation) supplemented with 0, 0.25 or 1 mM 3-MPA. Media was refreshed every 48 h. Measure-
ments of porcine MYH4-promoter activity and myotube diameters were quantified as described  previously10.
Real‑time quantitative PCR (QPCR) analyses. C2C12 cells were seeded at 150,000 cells per well of a 
6-well plate and switched to DM at ~ 80% confluence (day 0 of differentiation). Cells were then either treated 
with a range of 3-MPA doses (0–1 mM) from day 0 for five days or from day 4 for four days. DM was refreshed 
every 48 h. Wells were harvested into 200 µl RNase-free PBS every 24 h from day − 1 for the duration of each 
time-course. Total RNA was extracted using the High Pure RNA Isolation kit (Roche Diagnostics, Mannheim, 
Germany), then RNA was reverse transcribed into cDNA using random hexamer primers included in the Rever-
tAid RT First Strand cDNA Synthesis kit (Thermo Scientific, Vilnius, Lithuania). Relative mRNA expression for 
each gene was determined by real-time quantitative PCR (QPCR) and normalised using OliGreen to quantify 
total cDNA, as described  previously17. QPCR primers used in this study are reported  elsewhere3.
Statistical analyses. One- or two-way analysis of variance (ANOVA) was performed in GraphPad Prism 
(7.03) statistical software for data relating to the following assays: BrdU incorporation, porcine MYH4 pro-
moter activity, myotube diameter and QPCR. When appropriate (ANOVA P < 0.05), a post-hoc Bonferroni or 
Dunnett’s multiple comparison test was used to compare the 3-MPA doses and the vehicle control (PBS; 0 mM 
3-MPA). For myotube diameters, one-way ANOVA was performed, blocking for ‘well’, to account for the dif-
ferent fields of view. A student’s t-test was performed to show the expected effects of dibutyryl cyclic-AMP 
(dbcAMP) treatment on porcine MYH4-promoter activity. Statistical analyses performed in GenStat (17th edi-
tion) include: two-way ANOVA (time × treatment) for CK activity and CK activity normalised to DNA content 
(blocking for ‘plate’); two-way ANOVA (time × treatment) for multiple time-point DNA assays, (blocking for 
experiment when data was pooled from two separate experiments); one-way ANOVA for fusion index, and 
two-way ANOVA for frequency of nuclei number in MyHC+ cells (blocking for ‘well’). Data are presented as 
Means ± standard error of the mean (SEM).
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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